NCT06568198 is a Phase 2 clinical trial of Real tACS in Chronic Low-back Pain, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT06568198?

NCT06568198 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT06568198?

Interventions in NCT06568198: Real tACS, Sham tACS.

What condition does NCT06568198 study?

NCT06568198 studies Chronic Low-back Pain.

Is NCT06568198 still recruiting?

NCT06568198 is currently recruiting now. Last updated 16 March 2026.

Last reviewed 2026-03-16 · How we verify

NCT06568198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modulation Effect of tACS on Chronic Low Back Pain

Recruiting now Phase 2 Last updated 16 March 2026

What this trial tests

Phase 2 trial testing Real tACS in Chronic Low-back Pain in 80 participants. Currently enrolling.

Timeline

25 August 2025

Primary endpoint
1 February 2028

28 February 2028

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	80
Start date	25 August 2025
Primary completion	1 February 2028
Estimated completion	28 February 2028
Sites	1 location across United States

Drugs / interventions tested

Real tACS
Sham tACS

Conditions studied

Chronic Low-back Pain — all drugs for Chronic Low-back Pain →

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 60, any sex, with Chronic Low-back Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigating the modulation effect of tACS

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Low-back Pain

Currently open trials in the same condition.

NCT06891625 — Movement Performance in Persons With Chronic Back Pain · NA · recruiting
NCT06825390 — AuriculoTherapy NeuroImaging · NA · recruiting
NCT04824248 — Weight Reduction in CLBP · NA · recruiting
NCT07055802 — Effects Of Inversion Table Therapy Vs MT On Pain And Lumbar Flexibility In Patients With Chronic Low Back Pain · NA · active not recruiting
NCT06831994 — Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06568198 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 16 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06568198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing